HDAC9 and Alzheimer disease: Oyarzabal and Co. aimed at designing dual PDE5 and HDAC inhibitors as multitarget directed ligands for the treatment of AD, where the complex etiology of the disease suggests higher efficacy than the classical ‘one molecule-one target approach’.